KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Operating Margin (2016 - 2025)

CRISPR Therapeutics AG's Operating Margin history spans 11 years, with the latest figure at 17912.5% for Q4 2025.

  • For Q4 2025, Operating Margin fell 1773154.0% year-over-year to 17912.5%; the TTM value through Dec 2025 reached 18933.65%, down 1768327.0%, while the annual FY2025 figure was 18933.65%, 1768327.0% down from the prior year.
  • Operating Margin for Q4 2025 was 17912.5% at CRISPR Therapeutics AG, down from 14854.78% in the prior quarter.
  • Across five years, Operating Margin topped out at 84.67% in Q2 2021 and bottomed at 2192350.0% in Q4 2022.
  • The 5-year median for Operating Margin is 17912.5% (2025), against an average of 142655.16%.
  • The largest annual shift saw Operating Margin crashed -219122047bps in 2022 before it surged 219238458bps in 2023.
  • A 5-year view of Operating Margin shows it stood at 1129.53% in 2021, then tumbled by -193994bps to 2192350.0% in 2022, then soared by 100bps to 34.58% in 2023, then plummeted by -623bps to 180.96% in 2024, then plummeted by -9798bps to 17912.5% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Operating Margin are 17912.5% (Q4 2025), 14854.78% (Q3 2025), and 25708.97% (Q2 2025).